ArticleEClinicalMedicine2022

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.

Katrina M Pollock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.